Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $29.9 million.

  • Angiodynamics' Accumulated Expenses fell 2521.61% to $29.9 million in Q4 2025 from the same period last year, while for Nov 2025 it was $29.9 million, marking a year-over-year decrease of 2521.61%. This contributed to the annual value of $35.5 million for FY2025, which is 1357.73% down from last year.
  • According to the latest figures from Q4 2025, Angiodynamics' Accumulated Expenses is $29.9 million, which was down 2521.61% from $27.7 million recorded in Q3 2025.
  • Angiodynamics' 5-year Accumulated Expenses high stood at $41.1 million for Q2 2024, and its period low was $21.8 million during Q1 2023.
  • Its 5-year average for Accumulated Expenses is $30.6 million, with a median of $29.5 million in 2023.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 5440.51% in 2024, then tumbled by 2521.61% in 2025.
  • Quarter analysis of 5 years shows Angiodynamics' Accumulated Expenses stood at $27.7 million in 2021, then decreased by 4.26% to $26.5 million in 2022, then grew by 10.19% to $29.2 million in 2023, then skyrocketed by 36.54% to $39.9 million in 2024, then decreased by 25.22% to $29.9 million in 2025.
  • Its last three reported values are $29.9 million in Q4 2025, $27.7 million for Q3 2025, and $35.5 million during Q2 2025.